 | • レポートコード：MRC23Q36216 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（2-3日） • 産業分類：医療機器 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の非侵襲的出生前遺伝子検査技術市場について調査・分析し、世界の非侵襲的出生前遺伝子検査技術市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（NIPT、NIPTプラス）、用途別セグメント分析（染色体異常、生殖補助医療、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Illumina、Natera、LifeLabs、NiftyTest、Labcorp、Xcelom、Veritas、Sema4、CeGaT、BGI、Berry Genomics、Daan Gene、CapitalBio、Annoroad、Adiconなどが含まれています。世界の非侵襲的出生前遺伝子検査技術市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、非侵襲的出生前遺伝子検査技術市場規模を推定する際に考慮しました。本レポートは、非侵襲的出生前遺伝子検査技術の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、非侵襲的出生前遺伝子検査技術に関するビジネス上の意思決定に役立てることを目的としています。 ・非侵襲的出生前遺伝子検査技術市場の概要 - 非侵襲的出生前遺伝子検査技術のタイプ別セグメント - 世界の非侵襲的出生前遺伝子検査技術市場規模：タイプ別分析（NIPT、NIPTプラス） - 非侵襲的出生前遺伝子検査技術の用途別セグメント - 世界の非侵襲的出生前遺伝子検査技術市場規模：用途別分析（染色体異常、生殖補助医療、その他） - 世界の非侵襲的出生前遺伝子検査技術市場規模予測（2018年-2029年） ・非侵襲的出生前遺伝子検査技術市場の成長トレンド - 非侵襲的出生前遺伝子検査技術の地域別市場規模（2018年-2029年） - 非侵襲的出生前遺伝子検査技術市場ダイナミクス - 非侵襲的出生前遺伝子検査技術の業界動向 - 非侵襲的出生前遺伝子検査技術市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：NIPT、NIPTプラス - 世界の非侵襲的出生前遺伝子検査技術のタイプ別市場規模（2018年-2023年） - 世界の非侵襲的出生前遺伝子検査技術のタイプ別市場規模（2024年-2029年） ・用途別セグメント：染色体異常、生殖補助医療、その他 - 世界の非侵襲的出生前遺伝子検査技術の用途別市場規模（2018年-2023年） - 世界の非侵襲的出生前遺伝子検査技術の用途別市場規模（2024年-2029年） ・非侵襲的出生前遺伝子検査技術の地域別市場規模 - 北米の非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - アメリカの非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - ヨーロッパの非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - アジア太平洋の非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - 中国の非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - 日本の非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - 韓国の非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - インドの非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - オーストラリアの非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - 中南米の非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） - 中東・アフリカの非侵襲的出生前遺伝子検査技術市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Illumina、Natera、LifeLabs、NiftyTest、Labcorp、Xcelom、Veritas、Sema4、CeGaT、BGI、Berry Genomics、Daan Gene、CapitalBio、Annoroad、Adicon ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Noninvasive Prenatal Gene Testing Technology market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Noninvasive Prenatal Gene Testing Technology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Noninvasive Prenatal Gene Testing Technology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Noninvasive Prenatal Gene Testing Technology in Chromosomal Abnormalities is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Noninvasive Prenatal Gene Testing Technology include Illumina, Natera, LifeLabs, NiftyTest, Labcorp, Xcelom, Veritas, Sema4 and CeGaT, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Noninvasive Prenatal Gene Testing Technology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Prenatal Gene Testing Technology.
The Noninvasive Prenatal Gene Testing Technology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Noninvasive Prenatal Gene Testing Technology market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Noninvasive Prenatal Gene Testing Technology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Illumina
Natera
LifeLabs
NiftyTest
Labcorp
Xcelom
Veritas
Sema4
CeGaT
BGI
Berry Genomics
Daan Gene
CapitalBio
Annoroad
Adicon
Segment by Type
NIPT
NIPT Plus
Segment by Application
Chromosomal Abnormalities
Assisted Reproduction
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Noninvasive Prenatal Gene Testing Technology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Noninvasive Prenatal Gene Testing Technology Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 NIPT
1.2.3 NIPT Plus
1.3 Market by Application
1.3.1 Global Noninvasive Prenatal Gene Testing Technology Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Chromosomal Abnormalities
1.3.3 Assisted Reproduction
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Noninvasive Prenatal Gene Testing Technology Market Perspective (2018-2029)
2.2 Noninvasive Prenatal Gene Testing Technology Growth Trends by Region
2.2.1 Global Noninvasive Prenatal Gene Testing Technology Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Noninvasive Prenatal Gene Testing Technology Historic Market Size by Region (2018-2023)
2.2.3 Noninvasive Prenatal Gene Testing Technology Forecasted Market Size by Region (2024-2029)
2.3 Noninvasive Prenatal Gene Testing Technology Market Dynamics
2.3.1 Noninvasive Prenatal Gene Testing Technology Industry Trends
2.3.2 Noninvasive Prenatal Gene Testing Technology Market Drivers
2.3.3 Noninvasive Prenatal Gene Testing Technology Market Challenges
2.3.4 Noninvasive Prenatal Gene Testing Technology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Noninvasive Prenatal Gene Testing Technology Players by Revenue
3.1.1 Global Top Noninvasive Prenatal Gene Testing Technology Players by Revenue (2018-2023)
3.1.2 Global Noninvasive Prenatal Gene Testing Technology Revenue Market Share by Players (2018-2023)
3.2 Global Noninvasive Prenatal Gene Testing Technology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Noninvasive Prenatal Gene Testing Technology Revenue
3.4 Global Noninvasive Prenatal Gene Testing Technology Market Concentration Ratio
3.4.1 Global Noninvasive Prenatal Gene Testing Technology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Noninvasive Prenatal Gene Testing Technology Revenue in 2022
3.5 Noninvasive Prenatal Gene Testing Technology Key Players Head office and Area Served
3.6 Key Players Noninvasive Prenatal Gene Testing Technology Product Solution and Service
3.7 Date of Enter into Noninvasive Prenatal Gene Testing Technology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Noninvasive Prenatal Gene Testing Technology Breakdown Data by Type
4.1 Global Noninvasive Prenatal Gene Testing Technology Historic Market Size by Type (2018-2023)
4.2 Global Noninvasive Prenatal Gene Testing Technology Forecasted Market Size by Type (2024-2029)
5 Noninvasive Prenatal Gene Testing Technology Breakdown Data by Application
5.1 Global Noninvasive Prenatal Gene Testing Technology Historic Market Size by Application (2018-2023)
5.2 Global Noninvasive Prenatal Gene Testing Technology Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Noninvasive Prenatal Gene Testing Technology Market Size (2018-2029)
6.2 North America Noninvasive Prenatal Gene Testing Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Noninvasive Prenatal Gene Testing Technology Market Size by Country (2018-2023)
6.4 North America Noninvasive Prenatal Gene Testing Technology Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Noninvasive Prenatal Gene Testing Technology Market Size (2018-2029)
7.2 Europe Noninvasive Prenatal Gene Testing Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Noninvasive Prenatal Gene Testing Technology Market Size by Country (2018-2023)
7.4 Europe Noninvasive Prenatal Gene Testing Technology Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Noninvasive Prenatal Gene Testing Technology Market Size (2018-2029)
8.2 Asia-Pacific Noninvasive Prenatal Gene Testing Technology Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Noninvasive Prenatal Gene Testing Technology Market Size by Region (2018-2023)
8.4 Asia-Pacific Noninvasive Prenatal Gene Testing Technology Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Noninvasive Prenatal Gene Testing Technology Market Size (2018-2029)
9.2 Latin America Noninvasive Prenatal Gene Testing Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Noninvasive Prenatal Gene Testing Technology Market Size by Country (2018-2023)
9.4 Latin America Noninvasive Prenatal Gene Testing Technology Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Noninvasive Prenatal Gene Testing Technology Market Size (2018-2029)
10.2 Middle East & Africa Noninvasive Prenatal Gene Testing Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Noninvasive Prenatal Gene Testing Technology Market Size by Country (2018-2023)
10.4 Middle East & Africa Noninvasive Prenatal Gene Testing Technology Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Noninvasive Prenatal Gene Testing Technology Introduction
11.1.4 Illumina Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.1.5 Illumina Recent Development
11.2 Natera
11.2.1 Natera Company Detail
11.2.2 Natera Business Overview
11.2.3 Natera Noninvasive Prenatal Gene Testing Technology Introduction
11.2.4 Natera Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.2.5 Natera Recent Development
11.3 LifeLabs
11.3.1 LifeLabs Company Detail
11.3.2 LifeLabs Business Overview
11.3.3 LifeLabs Noninvasive Prenatal Gene Testing Technology Introduction
11.3.4 LifeLabs Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.3.5 LifeLabs Recent Development
11.4 NiftyTest
11.4.1 NiftyTest Company Detail
11.4.2 NiftyTest Business Overview
11.4.3 NiftyTest Noninvasive Prenatal Gene Testing Technology Introduction
11.4.4 NiftyTest Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.4.5 NiftyTest Recent Development
11.5 Labcorp
11.5.1 Labcorp Company Detail
11.5.2 Labcorp Business Overview
11.5.3 Labcorp Noninvasive Prenatal Gene Testing Technology Introduction
11.5.4 Labcorp Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.5.5 Labcorp Recent Development
11.6 Xcelom
11.6.1 Xcelom Company Detail
11.6.2 Xcelom Business Overview
11.6.3 Xcelom Noninvasive Prenatal Gene Testing Technology Introduction
11.6.4 Xcelom Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.6.5 Xcelom Recent Development
11.7 Veritas
11.7.1 Veritas Company Detail
11.7.2 Veritas Business Overview
11.7.3 Veritas Noninvasive Prenatal Gene Testing Technology Introduction
11.7.4 Veritas Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.7.5 Veritas Recent Development
11.8 Sema4
11.8.1 Sema4 Company Detail
11.8.2 Sema4 Business Overview
11.8.3 Sema4 Noninvasive Prenatal Gene Testing Technology Introduction
11.8.4 Sema4 Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.8.5 Sema4 Recent Development
11.9 CeGaT
11.9.1 CeGaT Company Detail
11.9.2 CeGaT Business Overview
11.9.3 CeGaT Noninvasive Prenatal Gene Testing Technology Introduction
11.9.4 CeGaT Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.9.5 CeGaT Recent Development
11.10 BGI
11.10.1 BGI Company Detail
11.10.2 BGI Business Overview
11.10.3 BGI Noninvasive Prenatal Gene Testing Technology Introduction
11.10.4 BGI Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.10.5 BGI Recent Development
11.11 Berry Genomics
11.11.1 Berry Genomics Company Detail
11.11.2 Berry Genomics Business Overview
11.11.3 Berry Genomics Noninvasive Prenatal Gene Testing Technology Introduction
11.11.4 Berry Genomics Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.11.5 Berry Genomics Recent Development
11.12 Daan Gene
11.12.1 Daan Gene Company Detail
11.12.2 Daan Gene Business Overview
11.12.3 Daan Gene Noninvasive Prenatal Gene Testing Technology Introduction
11.12.4 Daan Gene Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.12.5 Daan Gene Recent Development
11.13 CapitalBio
11.13.1 CapitalBio Company Detail
11.13.2 CapitalBio Business Overview
11.13.3 CapitalBio Noninvasive Prenatal Gene Testing Technology Introduction
11.13.4 CapitalBio Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.13.5 CapitalBio Recent Development
11.14 Annoroad
11.14.1 Annoroad Company Detail
11.14.2 Annoroad Business Overview
11.14.3 Annoroad Noninvasive Prenatal Gene Testing Technology Introduction
11.14.4 Annoroad Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.14.5 Annoroad Recent Development
11.15 Adicon
11.15.1 Adicon Company Detail
11.15.2 Adicon Business Overview
11.15.3 Adicon Noninvasive Prenatal Gene Testing Technology Introduction
11.15.4 Adicon Revenue in Noninvasive Prenatal Gene Testing Technology Business (2018-2023)
11.15.5 Adicon Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details